Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection
Authors:
Open Access
- 2 May 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (28) , 46020-46033
Abstract
Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infectionKeywords
This publication has 48 references indexed in Scilit:
- Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinomaMedicine, 2016
- Follicular helper T cell exhaustion induced by PD-L1 expression in hepatocellular carcinoma results in impaired cytokine expression and B cell help, and is associated with advanced tumor stages.2016
- Hepatitis B Virus–Specific and Global T-Cell Dysfunction in Chronic Hepatitis BGastroenterology, 2016
- HBV: Do I treat my immunotolerant patients?Liver International, 2016
- Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiationJournal of Hepatology, 2014
- Prognostic and predictive markers for the new immunotherapies.2014
- The co-inhibitory pathway and cellular immune imbalance in the progress of HBV infectionHepatology International, 2013
- Soluble PD‐1 rescues the proliferative response of simian immunodeficiency virus‐specific CD4 and CD8 T cells during chronic infectionImmunology, 2008
- Soluble PD-1 Facilitates 4-1BBL–Triggered Antitumor Immunity against Murine H22 Hepatocarcinoma In vivoClinical Cancer Research, 2007
- The function of programmed cell death 1 and its ligands in regulating autoimmunity and infectionNature Immunology, 2007